Andy May, DPhil
Chief Technology Officer
Andy May is Executive Vice President and Chief Technology Officer at Sana Biotechnology.
Prior to Sana, he led the Genome Engineering Platform at the Chan Zuckerberg Biohub, developing new genome engineering technologies for the treatment of human diseases. Before that, Andy was the Chief Scientific Officer of Caribou Biosciences, the first company to work on commercializing CRISPR-Cas systems for biomedical and biotechnology applications. At Caribou he built and led the research and development organization, helped raise venture and corporate financing and co-founded Intellia Therapeutics.
Previously, Andy held leadership positions in research and development at Fluidigm Corporation, leading programs in single-cell genomics, cell-free DNA sequencing, and structural proteomics and launched multiple commercial life-sciences systems. He held scientific positions at Thios Pharmaceuticals and Signature Biosciences and was a Wellcome Trust International Postdoctoral fellow at Stanford University. Andy has published many research articles in leading journals and is an inventor on over 100 national and international patents and pending patent applications.
Andy obtained his DPhil in molecular biophysics and his undergraduate degree in chemistry from the University of Oxford.